Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2013 09:59 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. Announces Pricing of Public Offering of Common Stock and Warrants

ANN ARBOR, Mich., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
August 12, 2013 14:29 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Announces Amendment of Series B Preferred Stock Certificate of Designations, Preferences and Rights

ANN ARBOR, Mich., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
August 07, 2013 16:05 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Reports Second-Quarter and First-Half 2013 Financial Results

ANN ARBOR, Mich., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
July 03, 2013 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences to Present at the JMP Securities Healthcare Conference

ANN ARBOR, Mich., July 3, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
May 08, 2013 16:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Reports First Quarter 2013 Financial Results

ANN ARBOR, Mich., May 8, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
May 03, 2013 16:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom to Host First Quarter 2013 Investor Call on May 8, 2013

ANN ARBOR, Mich., May 3, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
April 25, 2013 16:30 ET | Source: Aastrom Biosciences, Inc.

Aastrom to Hold Annual Meeting of Shareholders on May 2, 2013

ANN ARBOR, Mich., April 25, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe,...
April 19, 2013 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Announces First Patients Treated in ixCELL-DCM Clinical Study of ixmyelocel-T

ANN ARBOR, Mich., April 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe,...
April 09, 2013 16:12 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences to Present at Multiple Conferences in April

ANN ARBOR, Mich., April 9, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe,...
April 04, 2013 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Announces First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel-T

ANN ARBOR, Mich., April 4, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...